BTIG analyst, Amanda Murphy, reiterated the Buy rating on shares of Intellia Therapeutics (NASDAQ: NTLA) and raised the price target ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE